Martine A. Rothblatt - 15 Mar 2026 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Reporting relationship: Chairperson & CEO, Director
Issuer ticker: UTHR
Reported as of: 15 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 17:09:17 UTC
Prior SEC filing: 16 Mar 2026
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ John S. Hess, Jr. under Power of Attorney

Key filing fact

Martine A. Rothblatt filed Form 4 for UNITED THERAPEUTICS Corp (UTHR) on 17 Mar 2026.

Key facts

This page summarizes Martine A. Rothblatt's Form 4 filing for UNITED THERAPEUTICS Corp (UTHR).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 17:09.

Change

Previous filing in this sequence was filed on 16 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001106578 Primary reporting owner

ROTHBLATT MARTINE A

Relationship: Chairperson & CEO, Director
Address: C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING
Signature: /s/ John S. Hess, Jr. under Power of Attorney
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

UTHR transaction

Common Stock

Options Exercise

Transaction value
Shares: +32,499
Change %: +24999%
Price
Shares after: 32,629
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

UTHR transaction

Common Stock

Options Exercise

Transaction value
Shares: +37,080
Change %: +114%
Price
Shares after: 69,709
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

UTHR transaction

Common Stock

Tax liability

Transaction value
Shares: -13,637
Change %: -20%
Price: $536.12^*
Shares after: 56,072
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F2

UTHR transaction

Common Stock

Tax liability

Transaction value
Shares: -15,559
Change %: -28%
Price: $536.12^*
Shares after: 40,513
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F2

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 166
Date: 15 Mar 2026
Ownership: by Spouse

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 324,518
Date: 15 Mar 2026
Ownership: by Trust
Footnotes: F3

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 258,117
Date: 15 Mar 2026
Ownership: by Trust
Footnotes: F4

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 45,596
Date: 15 Mar 2026
Ownership: by Trust
Footnotes: F5

UTHR holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 10,962
Date: 15 Mar 2026
Ownership: by Trust
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UTHR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -32,499
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,499
Exercise price
Footnotes: F1, F7

UTHR transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -37,080
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,080
Exercise price
Footnotes: F1, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

Footnote F2

Represents the number of shares withheld by United Therapeutics for tax purposes, upon vesting of restricted stock units.

Footnote F3

Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

Footnote F4

Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Footnote F5

Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.

Footnote F6

Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.

Footnote F7

Shares received upon vesting of performance-based restricted stock units on March 15, 2026. Restricted stock units converted on a one-for-one basis into shares of common stock. These restricted stock units were granted on March 15, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .